Merck & Company Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.0% | -0.8% | +6.4% | +4.4% | -0.4% | -1.7% | +2.1% | +10.2% | +5.7% | -6.0% | +0.9% | |
| – | +0.7% | -2.2% | +21.5% | +5.6% | -3.9% | -8.5% | +4.4% | +28.3% | -8.5% | -19.5% | +4.8% | |
| – | -20.5% | -18.4% | +102.6% | +29.1% | -9.3% | -34.8% | -7.2% | +126.9% | -19.8% | -63.4% | +28.6% | |
| – | -19.1% | – | – | +28.5% | -6.2% | -32.6% | -6.6% | +111.3% | -20.0% | -60.9% | +25.2% | |
| – | -0.4% | +9.8% | +2.4% | -2.2% | -9.7% | +5.0% | +9.8% | +2.3% | +4.6% | -3.7% | +2.9% | |
| – | +3.7% | +2.4% | -0.6% | -3.5% | -2.2% | +1.4% | +6.5% | -2.4% | +3.3% | -2.7% | -4.2% | |
| – | – | – | – | – | +1.4% | +4.3% | +1.8% | +1.6% | -1.3% | – | – | |
| – | +0.1% | -0.1% | -0.1% | +2.5% | -0.1% | +0.1% | -0.4% | 0.0% | 0.0% | +0.0% | +0.0% | |
| – | -6.2% | -2.4% | -3.3% | +0.2% | -3.8% | -3.7% | -3.6% | +0.8% | +74.2% | -3.5% | -3.0% | |
| – | +5.5% | -5.2% | +5.4% | +5.8% | -3.1% | -5.7% | +2.6% | +13.4% | +8.5% | -1.7% | +6.1% | |
| – | +11.3% | -2.3% | +3.8% | +13.5% | -3.9% | -11.4% | +3.4% | +10.0% | -1.1% | -4.9% | +2.9% | |
| – | +86.8% | – | – | +2.5% | -6.9% | -53.6% | +5.4% | -2.0% | +105.2% | -15.2% | +15.6% | |
| – | +11.8% | -10.4% | +0.1% | +1.9% | +13.7% | -7.2% | +2.9% | +6.6% | +6.2% | -12.3% | -0.9% | |
| – | -0.9% | -7.5% | +11.5% | +0.8% | -1.5% | -2.8% | +1.4% | +17.7% | +17.0% | -0.2% | +9.4% | |
| – | -8.9% | +7.4% | +8.0% | +2.1% | +4.1% | +4.4% | +1.4% | +5.8% | +1.5% | -12.8% | -8.6% | |
| – | -5.6% | +5.2% | +6.2% | +2.0% | +2.7% | +4.8% | +3.6% | +5.5% | +1.2% | -8.7% | -5.2% | |
| – | +0.3% | -0.8% | +0.4% | -0.1% | +0.0% | -0.4% | -0.7% | -0.6% | -0.4% | -0.6% | +0.0% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.